

Natural Immune Response against COVID-19 in First Line Corona Warriors at Dhanbad and their Adjoining Districts of Jharkhand: A Prospective Study

B. K. Pandey

Asstt. Blood Center SNMMC, Dhanbad, Jharkhand, India

Abstract: Background: A study was required at the initial phase of continued Nobel COVID-19 pandemic to know the impact of infection and to set a guideline for treatment. In the correct knowledge IgG develops four weeks following infection after SARS-COV-2 Virus. IgG as a reliable antibody develops in 99% of individuals who are immunocompetent. A robust immunity is needed to handle disease caused by viruses and bacteria new to the community. Primary immunity depends on multiple factors. An intact immune system empowered by B&T cells, proper activation of complements & immunoglobins are all that needed for the faster healing of the disease. During the continued pandemic numerous mutations happened in COVID-19 viruses which threats to the community at the detection level of virus. In my study IgG was chosen as a reliable marker of sero conversion & it's may be helpful in deciding immunity status of an individual. This study is expected to assure following parameter whether a particular age or sex is more immune to disease? Whether in particular titre is beneficial & whether it is helpful in recovery from mild to moderate disease in hospitalized patients. **Method:** A SOP has been made in the department of blood centre for proper evaluation of donor's eligibility. Detailed clinical examination, donors nasal swab was taken their blood samples will be collected for CBC, total protein and IgG (anti-COVID-19 anti body). Properly filled consent paper will be collected with all safety measures keeping ethical issues in my study. All donors asked to submit RT-PCR reports. All healthy individuals will be chosen and their IgG titers will be measured, analyzed & compared with the available data on globally accessible sites available digitally. Manual charts & tables will be prepared for study based on age & sex of participants. A control value was set-up. Less than one is negative & more than 1 was taken positive on the basis of CLIA method. Age-wise comparisons were considered in both groups.

Keywords: Primary immunity, B&T cells, Nobel COVID-19 virus, Anti IgG antibody, Sero-conversion, RT-PCR

1. Results

Data 1: Age & Sex specific analysis of participants (152 males Vs 27 females) aged 20-70 years

Age	Male	Female
20-29	35	13
30-40	39	08
41-50	23	02
>50	10	00

Data 2: Antibody titres obtained by CLIA method from all participants (152 males Vs 27 females) aged 20-70 years. Anti-COVID- 19 antibody IgG were categorized as mild, moderate & high.

Age Group	Mild 1-10		Moderate 11-20		High 20-30	
	Male	Female	Male	Female	Male	Female
20-29	23	10	05	03	03	00
30-40	26	06	06	00	02	01
41-50	14	01	04	01	00	00
>50	16	01	08	00	04	00

2. Conclusions

74% cases were asymptomatic females. IgG was only mildly elevated. The infected females were largely pre-menopausal age group. Sero-conversion rates were higher in females as compared to males (86% vs 70%). These shows robust immune response in females in comparison to males.

Discussions:-Pre-menopausal adult women generally have stronger immune response than children, men or female during post-menopausal period. These are due to multiple reasons for those differences are like genetic factors, life style practices, co-morbidities, hormonal factors, immunity & ageing.

Financial Assistance: No financial taken from any Government or Private donations.

Interests of Conflicts: There is no interest of conflict.

References

- [1] World Health Organization. "Immunity passports" in the context of COVID-19. Availa' room/ commentaries/detail/ immunity-passports-in-the-context-of-COVID-19
- [2] World Health Organization. Statement on TBC seventh meeting of the International Health Comminee regarding the coronavirus disease (COVID-19) pandemic. Available from: 104-2021-s1alemem-on-lhe-seventh-meeling-ol1he-intemutional-heal1h-regulations-{200the-coronavirus-disease-(covid-19)-pandemic
- [3] Wajnberg A, MansourM, LevenE, etal. Humoral response and PCR positivity in patie City region, USA: an observational study. LancetMicrobe [lmemet]2020 [cited2021h1rps: /linkinghub. elsevier. eomfrctric/cfpiifS266652472030 1208
- [4] GuthmillerJJ, Stovicck0, WangJ. ctal. SARS-CoV-2Infection Severity Is Linked to: the Spike. mBio [lnrcmct] 2021 [cited2021Ytar26]; 12 (1): c02940-20, /mbio/1211/mBi-https://mbio. asm.

Volume 12 Issue 6, June 2023

www.ijsr.net

Licensed Under Creative Commons Attribution CC BY

- ondcomment/12/I/e02940-20
- [5] WuJ, LiangB, ChenC, et al. SARS-CoV-2infection induces sustained humoral immw following symptomatic COVID-19. *Nal Commun*2021; 12 (1): 1813.
- [6] HuangC, HuangL, WangY, et al. 6 – month consequences of COVID-19in patients dis>study. *The Lancet* [Internet] 2021 [cited2021Apr22]; 397 (10270): 220-32. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0140673620326568>
- [7] Arkhipova-, JenkinsI, Helf and M, Annstrong C, et al. Antibody Response After SARS-<Immunity: A Rapid Living Review. *AnnIntcm Med*2021;
- [8] ScowJ, Graham C, MerrickB, et al. Longinldi11al observation and decline of ncutralizi J months following SARS-CoV-2infectioninl1umnns. *NatMierobiol* [Internet]2020 [cil Available from: <http://www.nature.com/articles/41564-020-00813-8>
- [9] LongQ-X, TangX-J, ShiQ-L, et al. Clinical and immunological asscssme111ofasympt•Med [111emet]2020 [cited2021Apr22]: 26 (8): 1200-4. Available from: <http://www.nat>
- [10] Whealley AK, JunoJA, WangJJ, et al. Evolution of immune responses lo SARS-CoV-2iCommun [Internet]2021 [cited2021Apr22]; 12 (1): 1162. Available from: <http://www.nal>
- [11] DanJM, MateusJ, KaroY, et al. Immunological memory toSARS-CoV-2assessedforScience [Internet]2021 [cited 2021Mar26]; 371 (6529): eabf4063. Available from: <https://www.sciencemag.org/lookup/doi/10.1126/sciencceabf4063>
- [12] SchwarzkopfS, CcUular Immunity in COVID – 19 Convalescents with PCR – Confinncd ISARS-CoV-2-Sppccific IgG. *EmergInfectDis* [Ln1erne1]Availablefrom: <https://www3772article/su!!reSled citation>
- [13] SckineT, Perez-PottiA, Rivern-Ballesteros0. Et al. Robust T Cell Immunity in Conval Asymptomatic or Mild COVID-19. *Cell*2020; 183 (1): 158-168. el4.
- [14] Wheatley AK, JunoJA, WangJJ, et al. Evolution of immunity10SARS-CoV-2 [IntemtHIV/AIDS]; 2020 [cited2021Mar26). Available from: <http://medrxiv.org/lookup/doi/>
- [15] PolandGA, OvsyannikovaJG, KennedyRB. SARS-CoV-2immunity: review and appli candidates. *The Lancer* [Internet]2020 [cited2021Apr16]; 396 (10262): 1595-606. Avahtrps://linkinghub.elsevier.com/errieve/pii/S0140673620321371
- [16] EdridgeAWD, KaczorowskaJ, HosteACR, et al. Seasonal coronavirus protective imm Qnternet] 2020 [cited2021Mar26]; 26 (11): 1691-3. Availablefrom: <http://www.nature>
- [17] HuangAT, Garcia-CarrerasB, Hitchings MDT, et al. A systematic review of antibody1kinetics, correlates of protection, an association with severity. *NatCommun* (lotcmet]15); 11 (I): 4704. Availablefrom: <http://www.natprc.com/articles/s41467-020-18450-4>
- [18] GuoX, GuoZ, DuanC, et al. Long – Term Persistence of IgG Antibodies in SARS-CoVfIntnct]. *Infectious Diseases (exceptlilV/AIDS)*; 2020 [cited 2021Apr15]. Ava. <http://medrxiv.org/lookup/doi/10.1101/2020.02.12.20021386>
- [19] WuL-P, Wang-C, ChangY-H, et al. Duration of Antibody Responses after Severe A Infect Dis [Internert]2007 [cited2021Apr15]; 13 (10): 1562-4. Availablefrom: <http://www.hon> 0576 article.
- [20] AndersonDE, TanCW, ChiaWN, et al.Lackofcross-neutralizarionbySARSpaticnr! *MicrobesInfect*2020; 9 (1): 900-2.
- [21] AlshukairiAN, ZhaoJ, AJ-MozainiMA, WangY, DadaA, BaharoonSA, et al. Longc1syndromecoronavirus antibody responses in humans. *Saudi Ambia. EmergInfectDis*. '
- [22] Harvey RA, Rassen JA, Kabelac CA, et al. Association of SARS-CoV-2SeropositiveAInfection. *JAMAIntern ed* [Intemet] 2021 [cired2021Mar26); Available from: <https://jamanetwork.com/journals/jamaintemalmedicine/fullarticle/2776810>
- [23] LumleySF, O'DonnellID, Stoesser IE, Et al. Antibody Status and IncidenceofSARS-1Workers. *NEnglJMed* [Internet]2021 [cited 2021Mar26]; 384 (6): 533-40. Availablehnp://www.nejm.org/doi/10.1056/NEJMoa2034545
- [24] HansenCH, MichlmayrD, GubbelsSM, MolbakK, F. thelbergS. Assessmentofprotec1CoV-2among4millionPCR – tested individuals in Denmark in2020: A population – level Intemet]2021 [cited2021Mar27]; 397 (10280): !204-12. Availablefrom: <https://linkinf!hub.elsevier.com/retricve/pii/S0140673621005754>
- [26] !allVJ, FoulkesS, Charletl A, et al. SARS-CoV-2 infection rntcs of antibody-positive health – care workers in England: alarge, multicentre, prospective cohort study (SIREN).2021Apr15]; SO140673621006759. Availablefrom: [hups://linkinghub.elsevier.com/rel](https://linkinghub.elsevier.com/rel)
- [27] Wang P, NairMS, Liu L, et al. Antibody Resistance of SARS-CoV-2VariantsB.1.351 [cited2021Mar30]; Availablefrom: [http://www.naturc.com/nnicls/s41.\)](http://www.naturc.com/nnicls/s41.)) 86-021-0339
- [28] PlanasD, BnielT, GrzelakL, et al. Sensitiviry of infectious SARS-CoV-2B.1.1.7andB. I. *NatMed* (Intcmet]2021 [cited2021Mar30]; Availablefrom: <http://www.narurc.com/article>
- [29] Wang P, Wang M, Yu J, et al. Increased Resistance of SARS-CoV-2VariantP.1toAntMicrobiology: 2021 [cited2021Mar30j. Availablefrom: <http://biorxiv.orn/lookup/doi/>
- [30] ZhouD, DejnirattisaiW, SupasaP, et al. EvidenceofescapeofSARS-CoV-2variantB1inducedsera. *Cell* [Internet]2021 [cited2021Mar 30]; S0092867421002269. Availablehtnrs: /11inkinehub.elsevier.com/retrievfpri/S0092867-12I002269
- [31] AbdoolKarimSS, deOliveiraT. NewSARS-CoV-2Variants Clinical, PublicHealdJMed [Internet]2021 [cited2021Mar26]; NEJMc2100362. Availablefrom: <http://www.nejm.on!/doi/10.1056/NEJMc2100362>
- [32] WorldHealthOrganization. Diagnostic testing for SARS-CoV-2. Available from: <https://www.who.int/publications/i/item/dia!lnO>lic-tcsting-for-sars-cov-2>
- [33] World Health Organization. Adviceoatl1cuseofpoint-of – care in ununodiagnostictestsfohttps://www.who.int/news-room/commncraris/dctail/advice-on-the-usc-of-point-of-careKrammerF. Correlarcs of proction fromSARS-CoV-2infection. *TheLancet* [Internet